Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | TOP1 | P11387 | 3/20 | 0.33 |
| ▸ | CYCS | P99999 | 3/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.30 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094135 | 0.96 | STAT3 (0.45) | STAT3STAT1TOP1CHEK2PARP1 | |
| SCHEMBL5034725 | 0.87 | STAT3 (0.47) | STAT3STAT1TOP1CYCSABCG2 | |
| SCHEMBL351526 | 0.85 | STAT3 (0.43) | STAT3STAT1TOP1CYCSABCG2 | |
| SCHEMBL6231545 | 0.85 | STAT3 (0.36) | STAT3STAT1 | |
| SCHEMBL3125425 | 0.82 | STAT3 (0.49) | STAT3STAT1TOP1CYCS | |
| SCHEMBL351897 | 0.81 | STAT3 (0.45) | STAT3STAT1TOP1ABCG2 | |
| SCHEMBL1596068 | 0.81 | STAT3 (0.47) | STAT3STAT1TOP1CYCSABCG2 | |
| SCHEMBL1077710 | 0.78 | STAT3 (0.42) | STAT3STAT1 | |
| SCHEMBL6412535 | 0.77 | ABCG2 (0.45) | STAT3STAT1ABCG2 | |
| SCHEMBL455573 | 0.77 | STAT3 (0.67) | STAT3STAT1TOP1CYCSABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | PROGEN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7026347-B2 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | CELLGATE, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276444-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | STAT3 2163/4885STAT1 2279/4885TOP1 1006/4885 |
| US-20040152687-A1 | Porphyrin-polyamine conjugates for cancer therapy | SRM, PAICS, FOLH1 | STAT3 2163/4885STAT1 2279/4885TOP1 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.